Curium
Curium is one of the largest nuclear-medicine companies, developing 177Lu-PSMA-I&T (ECLIPSE) as a competitor to Pluvicto.
Private radiopharma group (SPECT and PET isotopes, generators). ECLIPSE phase 3 of 177Lu-PSMA-I&T met its rPFS endpoint in taxane-naive mCRPC; Japanese registrational trial with PeptiDream/PDRadiopharma enrolled its first patient February 2026. Regulatory submission plan under discussion with FDA.
177Lu-PSMA-I&T is a second PSMA radioligand, chemically different from Pluvicto, that has passed two phase 3 trials on progression but has not yet shown a survival benefit.
The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).